Skip to main content

Actavis-Allergan merger complete


DUBLIN — Actavis last week announced that its acquisition of Allergan has been completed in a transaction valued at $70.5 billion, a deal that creates one of the world’s top 10 pharmaceutical companies by sales revenue, according to the company, adding that annual revenues exceeding $23 billion are anticipated in 2015.


"The combination of Actavis and Allergan creates an exceptional global pharmaceutical company and a leader in a new industry model – Growth Pharma," said Brent Saunders, CEO and president of Actavis. "Anchored by world-renowned brand franchises, a leading global generics business, a premier pharmaceutical development pipeline and an experienced management team committed to maintaining highly efficient operations across the organization, we are creating an unrivaled foundation for long-term growth.”


Saunders went on to say that the company’s generics business “continues to hold an industry-leading position in First-to-File opportunities in the United States and more than 1,000 marketing authorizations globally,” giving Actavis a competitive edge within the industry. 


As reported previously, Actavis is set to take on a new global name — Allergan — pending shareholder approval. 

This ad will auto-close in 10 seconds